Programmable probiotics as next-generation living therapeutics: bridging synthetic biology and precision medicine

Engineered probiotics are rapidly redefining what's possible for living therapeutics. Instead of acting passively, these microbes can now home to disease sites, sense local signals, and deliver precisely the therapeutic activities our patients need - directly in situ and for extended periods. With the help of modular genetic circuits, synthetic biology is transforming once-commensal bacteria into sophisticated, programmable medicines. In this review, we highlight how these designer microbes are tackling inflammatory bowel disease, metabolic conditions, and cancer, and we offer a critical look at the strategies underpinning their safety, efficacy, and clinical translation. We also discuss the translational bottlenecks, such as biocontainment, regulatory complexity, and microbiome variability, that must be overcome as these living medicines move from concept toward routine clinical use. Ultimately, programmable probiotics stand poised to reshape pharmaceutical biotechnology, sitting squarely at the intersection of microbiology, engineering, and precision medicine.